1-phenyl-4-chlorocarbonylpiperazine | 65463-97-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-phenyl-4-chlorocarbonylpiperazine
• 英文别名: 4-phenyl-piperazine-1-carbonyl chloride；4-phenylpiperazine-1-carbonyl chloride
• CAS: 65463-97-0
• 化学式: C₁₁H₁₃ClN₂O
• 分子量: 224.69
• InChiKey: ALJWDTLMHKOUIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-phenyl-4-chlorocarbonylpiperazine 、 cyclohexanecarboxylic acid (4,4-diethoxy-butyl)-amide 生成 4-phenylpiperazine-1-carboxylic acid (4,4-diethoxybutyl)amide
  参考文献：
  名称：

  Medicaments

  摘要：

  描述了一种正式化合物(I)：其中R1和R2如文本中所定义，并且这些化合物旨在用于治疗以多巴胺受体活性失衡为特征的医疗条件。

  公开号：

  US20110046153A1

文献信息

• PHARMACEUTICAL COMPOUNDS
  申请人：Kiss Laszlo Erno

  公开号：US20120065191A1

  公开（公告）日：2012-03-15

  The invention relates to compounds and compositions for inhibiting the enzyme fatty acid amide hydrolase (FAAH), the use of the compounds in therapy and, in particular, for treating or preventing conditions whose development or symptoms are linked to substrates of the FAAH enzyme, and methods of treatment or prevention using the compounds and compositions.

  这项发明涉及抑制脂肪酰胺水解酶（FAAH）的化合物和组合物，以及在治疗中使用这些化合物，特别是用于治疗或预防与FAAH酶底物相关的疾病的发展或症状的条件，以及使用这些化合物和组合物进行治疗或预防的方法。
• [EN] MEDICAMENTS<br/>[FR] MÉDICAMENTS
  申请人：MOTAC NEUROSCIENCE LTD

  公开号：WO2009056805A1

  公开（公告）日：2009-05-07

  A compound of formula (I) is described: wherein R1 and R2 are as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.

  描述了一种化合物的化学式(I)：其中R1和R2如文本中定义的那样，这些化合物旨在用于治疗以多巴胺受体活性失衡为特征的医疗状况。
• Substituted piperidines as Par-1 Antagonists
  申请人：Jeske Mario

  公开号：US20120046268A1

  公开（公告）日：2012-02-23

  The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumour disorders.

  这项发明涉及新型取代哌啶，以及它们的制备方法，它们用于治疗和/或预防疾病，以及用于制备用于治疗和/或预防疾病的药物，特别是心血管疾病和肿瘤疾病。
• Diacyl indazole derivatives as lipase and phospholipase inhibitors
  申请人：Zoller Gerhard

  公开号：US20080287448A1

  公开（公告）日：2008-11-20

  The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof: Wherein X, R1 and R2 are as defined herein. The invention also relates to the use of these compounds as pharmaceutical products.

  该发明涉及一般式(I)或(II)的二酰基吲唑衍生物以及其药用可接受的盐：其中X，R1和R2如本文所定义。该发明还涉及将这些化合物用作药物产品。
• Substituted piperidines as Par-1 antagonists
  申请人：Jeske Mario

  公开号：US08987248B2

  公开（公告）日：2015-03-24

  The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumor disorders.

  本发明涉及新型取代哌啶，其制备方法，其用于治疗和/或预防疾病的用途，以及用于制备治疗和/或预防疾病的药物，特别是心血管疾病和肿瘤疾病。